Literature DB >> 12032865

Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma.

Mary L Alpaugh1, James S Tomlinson, Sina Kasraeian, Sanford H Barsky.   

Abstract

Inflammatory breast carcinoma (IBC) is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a human-scid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2K(d)-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/alpha, beta-catenin axis which mediates tumor cell-tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the effects of palpation on MARY-X with the effects of palpation on a derived dominant-negative E-cadherin mutant (H-2K(d)-E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24(met)) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10-->30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10-100-fold (P<0.001) only in MARY-X. The mechanism of this effect was through an immediate post-palpation release of circulating tumor emboli detected 2-3 min after palpation (P<0.01) by human cytokeratin 19 RT-PCR of extracted RNA from 300 microl of murine blood. Although circulating human tumor cell-derived growth factors (IGF-I, IGF-II, TGF-alpha and TGF-beta) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P>0.1). Our findings support the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in IBC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032865     DOI: 10.1038/sj.onc.1205389

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Expression of the blood-group-related antigens Sialyl Lewis a, Sialyl Lewis x and Lewis y in term placentas of normal, preeclampsia, IUGR- and HELLP-complicated pregnancies.

Authors:  Vassilis Minas; Ioannis Mylonas; Barbara Schiessl; Doris Mayr; Sandra Schulze; Klaus Friese; Udo Jeschke; Antonis Makrigiannakis
Journal:  Histochem Cell Biol       Date:  2007-06-06       Impact factor: 4.304

2.  Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.

Authors:  Michelle M Martínez-Montemayor; Raysa Rosario Acevedo; Elisa Otero-Franqui; Luis A Cubano; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2011-09-02       Impact factor: 2.900

Review 3.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

4.  Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma.

Authors:  Mary L Alpaugh; James S Tomlinson; Yin Ye; Sanford H Barsky
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  Nitric oxide mediates cell aggregation and mesenchymal to epithelial transition in anoikis-resistant lung cancer cells.

Authors:  Phattrakorn Powan; Pithi Chanvorachote
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

6.  Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.

Authors:  Ann H Klopp; Lara Lacerda; Anshul Gupta; Bisrat G Debeb; Travis Solley; Li Li; Erika Spaeth; Wei Xu; Xiaomei Zhang; Michael T Lewis; James M Reuben; Savitri Krishnamurthy; Mauro Ferrari; Rogério Gaspar; Thomas A Buchholz; Massimo Cristofanilli; Frank Marini; Michael Andreeff; Wendy A Woodward
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

7.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.

Authors:  Yi Xiao; Yin Ye; Kurtis Yearsley; Susie Jones; Sanford H Barsky
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

8.  Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.

Authors:  Helen O Oladapo; Michael Tarpley; Scott J Sauer; Kezia A Addo; Shalonda M Ingram; Dillon Strepay; Ben K Ehe; Lhoucine Chdid; Michael Trinkler; Jose R Roques; David B Darr; Jodie M Fleming; Gayathri R Devi; Kevin P Williams
Journal:  Cancer Lett       Date:  2017-09-28       Impact factor: 8.679

9.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

Authors:  Deborah Silvera; Rezina Arju; Farbod Darvishian; Paul H Levine; Ladan Zolfaghari; Judith Goldberg; Tsivia Hochman; Silvia C Formenti; Robert J Schneider
Journal:  Nat Cell Biol       Date:  2009-06-14       Impact factor: 28.824

10.  Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis.

Authors:  Salomé S Pinho; Celso A Reis; Fátima Gärtner; Mary L Alpaugh
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.